EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study

Binliang Liu iD, Zongbi Yi, Can Tian, Jian Deng, Ronghua Feng, Zhe-Yu Hu, Ning Xie, Yongxin Li, Jiuda Zhao, Tao Wu, Quchang Ouyang iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf277 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Binliang Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South Unive…. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Trastuzumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance THP (trastuzumab + paclitaxel + pertuzumab) and THPy (trastuzumab + paclitaxel + pyrotinib) are widely used as first-line regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in China. However, direct comparative data on their efficacy and safety remain scarce.

Objective

To evaluate and compare the clinical outcomes of THPy and THP in the first-line treatment of HER2-positive MBC to guide clinical decision-making.

Design

Real-world, multicenter retrospective study conducted from 2020 to 2024.

Setting

Five large breast cancer centers in China.

Participants

A total of 145 patients with HER2-positive MBC were included before propensity score matching (PSM). After PSM, 76 patients (38 in each group) were analyzed. Intervention(s) or Exposure(s) Patients received either THP (trastuzumab + paclitaxel + pertuzumab) or THPy (trastuzumab + paclitaxel + pyrotinib) as first-line treatment. Main Outcome(s) and Measure(s) The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate, and safety profile.

Results

Before PSM, 145 patients were included, with the median follow-up of 9.4 months. The ORR was significantly higher in the THPy group (75.0%) compared to the THP group (56.8%; P = .023). Median PFS showed a trend favoring THPy (19.80 months vs 15.57 months; Log-rank P = .343). After PSM, 76 patients were matched, with the median PFS of 24.33 months versus 14.50 months for THPy and THP groups, respectively. Though the difference in PFS was not statistically significant (Log-rank P = .309), THPy demonstrated a higher ORR compared to THP (78.9% vs 57.9%; P = .048). Further subgroup analysis revealed greater benefits of THPy, particularly in patients with prior neoadjuvant therapy (hazard ratio [HR] = 0.261; 95% CI: 0.072-0.940). Regarding safety, THPy was associated with a higher incidence of grade 3/4 diarrhea (26.6% vs 3.1%) as well as increased rates of neutropenia, anemia, alanine aminotransferase elevation, fatigue, and peripheral neuropathy compared to THP. Conclusion and Relevance Both THP and THPy are effective first-line options for HER2-positive MBC. While THPy demonstrates a higher ORR and a trend toward longer PFS, it also carries a higher incidence of adverse events, particularly diarrhea. These findings offer preliminary insights that may help inform treatment decisions, pending further validation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedTrastuzumabAcrylamidesTaxoidsHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesRetrospective StudiesAdultChinaAgedPaclitaxelNeoplasm MetastasisBridged-Ring CompoundsAminoquinolinesEast Asian People

Stichwörter der Autor:innen

HER2-positiveTHPTHPybreast cancerfirst-linereal-world study

Substanzen

Antibodies, Monoclonal, HumanizedTrastuzumabErb-b2 Receptor Tyrosine KinasesAcrylamidesTaxoidsPaclitaxelBridged-Ring CompoundsAminoquinolinespertuzumabpyrotinib

Autor:innen und Institutionen

  • Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
  • Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
  • Department of Thyroid Breast Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421009, China.
  • Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University, Changde 415000, China.
  • Department of Oncology, Hunan Institute of Schistosomiasis Control (The Third People's Hospital of Hunan Province), Yueyang 414000, China.
  • Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University, Xining 810000, China.

ORCID-Profile: Binliang Liu, Quchang Ouyang

Förderung

  • Provincial Natural Science Foundation of China

Zitieren

APA

Liu, B., Yi, Z., Tian, C., Deng, J., Feng, R., Hu, Z. Y., Xie, N., Li, Y., Zhao, J., Wu, T., & Ouyang, Q. (2025). Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf277

Vancouver

Liu B, Yi Z, Tian C, Deng J, Feng R, Hu ZY, et al. Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf277

BibTeX
@article{Liu2025,
  author = {Liu, Binliang and Yi, Zongbi and Tian, Can and Deng, Jian and Feng, Ronghua and Hu, Zhe-Yu and Xie, Ning and Li, Yongxin and Zhao, Jiuda and Wu, Tao and Ouyang, Quchang},
  title = {Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf277}
}
Kostenlos starten →